Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Vermont Tech Scene.
Press releases published on September 4, 2025
Gain Therapeutics Receives Australian Approval of Phase 1b Dosing Extension and Reports Positive Independent Data Monitoring Committee Recommendation
GlobeNewswire
·
September 4, 2025
Ongoing Phase 1b trial of GT-02287 to be extended by an additional nine months for participants who enrolled in the original three-month study design The independent data monitoring committee (DMC) met recently and recommended to continue the study with no …
MicroCloud Hologram Inc. (NASDAQ HOLO) Announces Robust Net Profit and Financial Results for the First Half of 2025
GlobeNewswire
·
September 4, 2025
SHENZHEN, China, Sept. 04, 2025 (GLOBE NEWSWIRE) -- MicroCloud Hologram Inc. reported a significant year-over-year turnaround to profitability in the first half of 2025. The Company's net profit for the first half of 2025 was RMB 238.1 million (US$33.1 …
Aeries Technology Announces Major Expansion Plans in India and Mexico, Adding 500 New Roles to Support Global Growth
GlobeNewswire
·
September 4, 2025
NEW YORK, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Aeries Technology, Inc. (NASDAQ: AERT), a global leader in AI-powered business transformation and Global Capability Center (GCC) services, today announced ambitious growth plans to expand its talent footprint …
Roadzen Inc. Announces Strategic Equity Financing of Approximately $4.5 Million for Its India Subsidiary at an $84 Million Pre-Money Valuation
GlobeNewswire
·
September 4, 2025
Raise anchored by marquee investors, including leading family offices and institutional investors in India. Values Roadzen’s India Subsidiary, contributing less than 60% of global revenues, at approximately a 25% premium to the Nasdaq-listed parent company …
DeepBrain AI Launches Automated UGC Ad Videos
GlobeNewswire
·
September 4, 2025
PALO ALTO, Calif., Sept. 04, 2025 (GLOBE NEWSWIRE) -- DeepBrain AI, a leading generative artificial intelligence company, today announced the launch of a new automated advertising solution that generates product-use videos through AI avatars using only a …
dLocal Announces Pricing of Secondary Offering
GlobeNewswire
·
September 4, 2025
MONTEVIDEO, Uruguay, Sept. 04, 2025 (GLOBE NEWSWIRE) -- DLocal Limited (“dLocal”), (NASDAQ:DLO) a technology-first payments platform, today announced the pricing of a previously announced secondary offering of 15,000,000 Class A common shares by an entity …
CorVista Health Announces Publication of Real-World Case Series in the Journal of the American College of Cardiology Exploring its Non-Invasive Test for Earlier Diagnosis of Pulmonary Hypertension
GlobeNewswire
·
September 4, 2025
BETHESDA, Md., Sept. 04, 2025 (GLOBE NEWSWIRE) -- CorVista Health today announced the publication of a new case series in the Journal of the American College of Cardiology (JACC), showcasing real-world clinical applications of the CorVista System®, a novel …
TG Therapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
GlobeNewswire
·
September 4, 2025
NEW YORK, Sept. 04, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the H.C. Wainwright 27th Annual Global Investment Conference, …
Nuvectis Pharma to Participate at the H.C. Wainwright 27th Annual Global Investment Conference
GlobeNewswire
·
September 4, 2025
Fort Lee, NJ, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious …
Zevra Therapeutics Presents Positive New Data Supporting Foundational Role of MIPLYFFA® (arimoclomol) for the Treatment of Niemann-Pick Disease Type C at the International Congress of Inborn Errors of Metabolism (ICIEM)
GlobeNewswire
·
September 4, 2025
New data from pre-specified analysis shows patients on concomitant miglustat who switched from placebo to MIPLYFFA experienced a decline in annual disease progression Nomination for Best Poster Award received for poster highlighting MIPLYFFA’s …
Digi Power X, Via Wholly-Owned Subsidiary US Data Centers Inc., Awarded Tier 3 ANSI/TIA-942-C “TIA-942 Ready” Certification for ARMS 200 AI Modular Platform
GlobeNewswire
·
September 4, 2025
This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated May 30, 2025 to its short form base shelf prospectus dated May 15, 2025. MIAMI, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Digi Power X Inc. (“ …
SAIC Announces Second Quarter of Fiscal Year 2026 Results
GlobeNewswire
·
September 4, 2025
Revenues of $1.77 billion; approximately (3)% revenue contraction Net bookings of $2.6 billion; book-to-bill ratio of 1.5, trailing twelve months book-to-bill ratio of 1.0 Year-to-date net bookings of $5.0 billion; year-to-date book-to-bill ratio of 1.4 …
SPEAR Study Group to Present its Recommended Long COVID Antibody Study Design Featuring Invivyd’s VYD2311 At RECOVER-TLC Workshop September 9-10, 2025
GlobeNewswire
·
September 4, 2025
SPEAR proposal reflects current evidence on monoclonal antibodies in treatment for Long COVID and identifies VYD2311 as a promising next-generation candidate for the clinical study Recommendation is for a robust, comprehensive, translational study to …
Immunocore to present at upcoming investor conferences
GlobeNewswire
·
September 4, 2025
Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England …
Neuphoria Therapeutics Completes Target Enrollment in Phase 3 AFFIRM-1 Trial of BNC-210 in Social Anxiety Disorder (SAD)
GlobeNewswire
·
September 4, 2025
BURLINGTON, Mass., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (Nasdaq: NEUP) (“Neuphoria” or the “Company”), a clinical-stage biotechnology company developing impactful treatments for neuropsychiatric disorders, today announced the …
Hinge Bio Expands Leadership Team to Drive Clinical Development of GEM-DIMER™ Programs and Announces Publication in Scientific Reports
GlobeNewswire
·
September 4, 2025
Paul Brunetta, M.D., joins as Chief Medical Officer; Kristen Quigley joins as Chief Clinical Operations Officer; Alpana Naresh, Ph.D., joins as Vice President and Head, CMC Strategy and Manufacturing Hinge Bio publishes differentiated in vivo data …
NextCure to Present at the H.C. Wainwright 27th Annual Global Investment Conference
GlobeNewswire
·
September 4, 2025
BELTSVILLE, Md., Sept. 04, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced that it …
Climb Bio to Host Webcast Highlighting CLYM116 and the IgA Nephropathy (IgAN) Opportunity on September 29, 2025
GlobeNewswire
·
September 4, 2025
WELLESLEY HILLS, Mass., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced details for the CLYM116 webcast event, which is set for …
C4 Therapeutics Highlights Recent Achievement in Biogen Collaboration
GlobeNewswire
·
September 4, 2025
WATERTOWN, Mass., Sept. 04, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that its partner Biogen has had its …
Breckenridge Distillery and Denver Broncos Kick Off Fifth Year of Partnership with New Lineup of Spirits, Including Limited-Edition Broncos Honey Whiskey
GlobeNewswire
·
September 4, 2025
BRECKENRIDGE, Colo., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Breckenridge Distillery, an award-winning craft distillery and spirits brand by Tilray Brands, Inc. (NASDAQ: TLRY; TSX: TLRY), is raising a glass to its fifth consecutive year as an official partner …